Zhende Dou
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Zhende Dou has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Bin Zhang
School of Pharmacy, Health Science Center, Ningbo University, Ningbo 315211, China
1 shared publication - Haoji Xie
Immunology Innovation Team, School of medicine, Ningbo University, Ningbo 315211, Zhejiang, China
1 shared publication - Jiale Zhou
Immunology Innovation Team, School of medicine, Ningbo University, Ningbo 315211, Zhejiang, China
1 shared publication - Ning Wang
Institute of Drug Discovery Technology, Ningbo University, Ningbo 315211, China
1 shared publication - Xiao Wang
Health Science Center, Ningbo University, Ningbo 315211, China
1 shared publication - Xinyi Tan
Immunology Innovation Team, School of medicine, Ningbo University, Ningbo 315211, Zhejiang, China
1 shared publication
Latest Publications
- Open Access
- 20 February 2021
- Published by MDPI AG in Antibiotics
- Vol. 10 (2) , 208
A Novel Ivermectin-Derived Compound D4 and Its Antimicrobial/Biofilm Properties against MRSA
Methicillin-resistant Staphylococcus aureus (MRSA) and its biofilms infection is still a serious threat to global health. It is urgent to develop efficient drugs by repositioning or designing drugs to solve this problem. In this study, the antibacterial/biofilm activity and mechanisms of ivermectin (D) and its 4″-position amino substitution derivative (D4) against MRSA were investigated. The minimum inhibitory concentration (MIC) of D was 20 μg/mL, which is four times higher than D4 (MIC = 5 μg/mL). The mechanism research demonstrated that D4 was more potent than D at destroying bacterial cell wall, permeating cell membrane (6.25–36.0% vs 1.92–6.04%) and binding to MRSA genomic DNA. Moreover, after incubation with 10–40 μg/mL D4 for 24 h, the percentages of biofilm decreased by 21.2–92.9%, which was more effective than D (no significant change at 40 μg/mL). The antibiofilm effect is achieved by regulating the expression of related genes (RSH, relQ, rsbU, sigB, spA, and icaD). Additionally, though the higher hemolysis makes D4 a safety risk for intravenous injection, other administration options could be considered as well. Therefore, all the results have indicated that D4 may be a potential candidate compound for the treatment of MRSA and its biofilm infections.
- 20 February 2021
- Published by MDPI AG in Antibiotics
- Vol. 10 (2) , 208
Open AccessA Novel Ivermectin-Derived Compound D4 and Its Antimicrobial/Biofilm Properties against MRSA
Methicillin-resistant Staphylococcus aureus (MRSA) and its biofilms infection is still a serious threat to global health. It is urgent to develop efficient drugs by repositioning or designing drugs to solve this problem. In this study, the antibacterial/biofilm activity and mechanisms of ivermectin (D) and its 4″-position amino substitution derivative (D4) against MRSA were investigated. The minimum inhibitory concentration (MIC) of D was 20 μg/mL, which is four times higher than D4 (MIC = 5 μg/mL). The mechanism research demonstrated that D4 was more potent than D at destroying bacterial cell wall, permeating cell membrane (6.25–36.0% vs 1.92–6.04%) and binding to MRSA genomic DNA. Moreover, after incubation with 10–40 μg/mL D4 for 24 h, the percentages of biofilm decreased by 21.2–92.9%, which was more effective than D (no significant change at 40 μg/mL). The antibiofilm effect is achieved by regulating the expression of related genes (RSH, relQ, rsbU, sigB, spA, and icaD). Additionally, though the higher hemolysis makes D4 a safety risk for intravenous injection, other administration options could be considered as well. Therefore, all the results have indicated that D4 may be a potential candidate compound for the treatment of MRSA and its biofilm infections.